Section Arrow
IBRX.NASDAQ
- ImmunityBio
Quotes are at least 15-min delayed:2025/03/28 08:23 EDT
Last
 3.36
+0.58 (+20.86%)
Day High 
3.375 
Prev. Close
2.78 
1-M High
3.51 
Volume 
16.43M 
Bid
3.31
Ask
3.33
Day Low
2.78 
Open
2.78 
1-M Low
2.68 
Market Cap 
2.37B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 2.81 
20-SMA 2.89 
50-SMA 3.08 
52-W High 10.53 
52-W Low 2.28 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.62/-0.36
Enterprise Value
2.87B
Balance Sheet
Book Value Per Share
-0.57
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
14.75M
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed:2025/03/28 08:23 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.